Anna Sicuranza

786 total citations
40 papers, 295 citations indexed

About

Anna Sicuranza is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Anna Sicuranza has authored 40 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 19 papers in Genetics and 13 papers in Molecular Biology. Recurrent topics in Anna Sicuranza's work include Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Multiple Myeloma Research and Treatments (11 papers). Anna Sicuranza is often cited by papers focused on Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Multiple Myeloma Research and Treatments (11 papers). Anna Sicuranza collaborates with scholars based in Italy, Ireland and United Kingdom. Anna Sicuranza's co-authors include Monica Bocchia, Emanuele Cencini, Alessandro Gozzetti, Donatella Raspadori, Alberto Fabbri, Marzia Defina, Sara Galimberti, Claudia Baratè, Elisabetta Abruzzese and Elisabetta Zappone and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Frontiers in Immunology.

In The Last Decade

Anna Sicuranza

36 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Sicuranza Italy 11 142 94 73 71 71 40 295
Shin‐ichi Fuchida Japan 11 169 1.2× 107 1.1× 87 1.2× 55 0.8× 44 0.6× 38 294
R. Champlin United States 6 162 1.1× 114 1.2× 114 1.6× 70 1.0× 55 0.8× 8 398
Daiki Karigane Japan 10 140 1.0× 50 0.5× 128 1.8× 80 1.1× 54 0.8× 31 337
Maria Regina Régis Silva Brazil 11 103 0.7× 69 0.7× 94 1.3× 51 0.7× 62 0.9× 31 268
K. Bienemann Germany 9 70 0.5× 125 1.3× 39 0.5× 265 3.7× 36 0.5× 12 367
Adriano Salaroli Italy 11 182 1.3× 46 0.5× 36 0.5× 63 0.9× 130 1.8× 29 251
S. K. China 11 176 1.2× 46 0.5× 85 1.2× 46 0.6× 61 0.9× 23 337
Masaki Toshima Japan 7 143 1.0× 54 0.6× 155 2.1× 25 0.4× 64 0.9× 16 329
Fabio Guolo Italy 10 112 0.8× 127 1.4× 78 1.1× 91 1.3× 36 0.5× 46 306
Evelyne D’Incan France 10 311 2.2× 98 1.0× 119 1.6× 51 0.7× 88 1.2× 23 410

Countries citing papers authored by Anna Sicuranza

Since Specialization
Citations

This map shows the geographic impact of Anna Sicuranza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Sicuranza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Sicuranza more than expected).

Fields of papers citing papers by Anna Sicuranza

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Sicuranza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Sicuranza. The network helps show where Anna Sicuranza may publish in the future.

Co-authorship network of co-authors of Anna Sicuranza

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Sicuranza. A scholar is included among the top collaborators of Anna Sicuranza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Sicuranza. Anna Sicuranza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sicuranza, Anna, et al.. (2025). The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers. Frontiers in Oncology. 15. 1546813–1546813. 1 indexed citations
2.
3.
Sicuranza, Anna, et al.. (2025). Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia. Annals of Hematology. 104(5). 2737–2743.
4.
Sicuranza, Anna, et al.. (2024). Prognostic Impact of CD47 Overexpression in Patients with Acute Myeloid Leukemia. Blood. 144(Supplement 1). 6084–6084.
5.
Sicuranza, Anna, Elisabetta Abruzzese, Valentina Giai, et al.. (2023). Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells. Frontiers in Pharmacology. 14. 1194712–1194712. 9 indexed citations
6.
Cencini, Emanuele, Anna Sicuranza, Alberto Fabbri, et al.. (2023). The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study. Leukemia & lymphoma. 64(10). 1634–1642. 3 indexed citations
7.
Cencini, Emanuele, et al.. (2023). Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications. Current Oncology. 30(7). 6111–6133. 17 indexed citations
8.
Cencini, Emanuele, Natale Calomino, Anna Sicuranza, et al.. (2023). Are small lymphocytic lymphoma and chronic lymphocytic leukemia the same disease? The unsolved dilemma. Journal of Chemotherapy. 36(6). 501–505. 2 indexed citations
9.
Fiorino, Fabio, Annalisa Ciabattini, Anna Sicuranza, et al.. (2022). The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients. Frontiers in Immunology. 13. 1017863–1017863. 15 indexed citations
10.
Gozzetti, Alessandro, et al.. (2022). Drug resistance and minimal residual disease in multiple myeloma. Cancer Drug Resistance. 5(1). 171–183. 8 indexed citations
11.
Gozzetti, Alessandro, et al.. (2022). Long-term CR Multiple Myeloma Patients Show Cured or MGUS-likeMinimal Residual Disease Pattern by Next Generation Flow. Reviews on Recent Clinical Trials. 17(2). 92–96. 1 indexed citations
12.
Vanni, Francesca, Anna Kabanova, Francesca Cattaneo, et al.. (2021). A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis. Pharmacological Research. 174. 105965–105965. 1 indexed citations
13.
Gozzetti, Alessandro, Anna Sicuranza, Elisabetta Zappone, et al.. (2020). Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. Frontiers in Oncology. 10. 570187–570187. 12 indexed citations
14.
Gozzetti, Alessandro, Anna Sicuranza, Elisabetta Zappone, et al.. (2019). LONG TERM SAFETY AND EFFICACY OF DARATUMUMAB RAPID INTRAVENOUS INFUSION (90 MINUTES) AFTER THE THIRD DOSE IN MULTIPLE MYELOMA PATIENTS. Clinical Lymphoma Myeloma & Leukemia. 19(10). e147–e148.
15.
16.
Bocchia, Monica, Sara Galimberti, Antonella Gozzini, et al.. (2014). ATHEROTHROMBOTIC RISK ASSESSMENT DURING TYROSINE KINASE INHIBITORS TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS: NEW INSIGHT?. Haematologica. 99. 533–534. 1 indexed citations
17.
Bocchia, Monica, et al.. (2014). Peptide vaccines for hematological malignancies: a missed promise?. International Journal of Hematology. 99(2). 107–116. 7 indexed citations
18.
Puccetti, Luca, Sara Galimberti, Antonella Gozzini, et al.. (2013). Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?. Blood. 122(21). 1482–1482. 6 indexed citations
19.
Forconi, Francesco, Emanuele Cencini, Elisa Sozzi, et al.. (2011). Insight into the behavior of hairy cell leukemia by immunogenetic analysis. Leukemia & lymphoma. 52(sup2). 103–107. 3 indexed citations
20.
Sozzi, Elisa, Teresa Amato, Surinder S. Sahota, et al.. (2010). Lack of allelic exclusion by secondary rearrangements of tumour B‐cell receptor light chains in hairy cell leukaemia. Hematological Oncology. 29(1). 31–37. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shin‐ichi Fuchida Breakdown of academic impact, for papers by R. Champlin Breakdown of academic impact, for papers by Daiki Karigane Breakdown of academic impact, for papers by Maria Regina Régis Silva Breakdown of academic impact, for papers by K. Bienemann Breakdown of academic impact, for papers by Adriano Salaroli Breakdown of academic impact, for papers by S. K. Breakdown of academic impact, for papers by Masaki Toshima Breakdown of academic impact, for papers by Fabio Guolo Breakdown of academic impact, for papers by Evelyne D’Incan
Rankless by CCL
2026